Tiffany A. Traina, MD

Articles

Dr. Traina on the FDA Approval of Trastuzumab Deruxtecan for HER2+ Breast Cancer

December 21st 2019

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) for patients with HER2-positive, locally advanced, or metastatic breast cancer who have been treated with trastuzumab (Herceptin) and pertuzumab (Perjeta) and have disease progression after ado-trastuzumab emtansine (T-DM1; Kadcyla).

Dr. Traina on Conversations on Extended Adjuvant Therapy With Neratinib in HER2+ Breast Cancer

July 12th 2019

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses patient conversations regarding extended adjuvant therapy with neratinib (Nerlynx) in early-stage HER2-positive breast cancer.

Dr. Traina on PARP Inhibition in BRCA-Mutated Breast Cancer

March 19th 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the prevalence of BRCA mutations in triple-negative breast cancer (TNBC).

Dr. Traina Discusses Neratinib in HER2+ Breast Cancer

February 17th 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neratinib (Nerlynx) in HER2-positive breast cancer.

Dr. Traina on Treatment Considerations for HER2+ Breast Cancer

February 3rd 2018

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, on considerations for the treatment of patients with HER2-positive breast cancer.